DIABETES AND COVID-19 INFECTION: CLINICAL ANALYSIS AND TREATMENT EFFECTIVENESS BASED ON THE TASHKENT EXPERIENCE
Keywords:
diabetes mellitus, COVID-19, metformin, insulin, DPP4 inhibitors, sulfonylureasAbstract
With the onset of the COVID-19 pandemic, researchers began to investigate the pathogenetic mechanisms causing the infection and its complications, to analyze patient groups with chronic diseases, and to develop effective methods for combating both the acute and chronic consequences of the infection. This study analyzed data from 5,023 patients who had contracted COVID-19 between April and December 2020. The patients were divided into four groups: those without diabetes mellitus (3,648), with type 1 diabetes (213), with type 2 diabetes (763), and with newly diagnosed diabetes during COVID-19 (399). The study results showed that clinical symptoms such as shortness of breath, chest pain, and arrhythmia were more pronounced in patients with diabetes, especially those with type 2. Patients who had been taking sulfonylureas reported shortness of breath more frequently.
References
Wu C, Chen X, Cai Y, et al. Risk Factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934-943. doi: https://doi.org/10.1001/jamainternmed.2020.0994 10. Gupta R, Ghosh A, Singh AK, Misra A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab Syndr. 2020;14(3):211-212. doi: https
Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: A review of pathogenesis. Indian J Endocrinol Metabol. 2012;16(S1):S27-S36. doi: https://doi.org/10.4103/2230-8210.94253
Peleg Y, Weerarathna T, McCarthy JS, Davis T. Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev. 2007;23(1):3-13. doi: https://doi.org/10.1002/dmrr.682
Alieva AV, Ismailov SI, Rahimova GN. Epidemiology of diabetes and prediabetes in Uzbekistan: Screening results. Health Sci J. 2018;12(6):609. doi: https://doi.org/10.21767/1791-809X.1000609
Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID‐19. Diabetes Metab Res Rev. 2020;36(7). doi: https://doi.org/10.1002/dmrr.3319
Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;(55):2000547.
Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020;8(10):813-822. doi: https://doi.org/10.1016/S2213-8587(20)30272-2
Holman N, Knighton P, Kar P, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020;8(10):823-833. doi: https://doi.org/10.1016/S2213-8587(20)30271-0
Singh AK, Singh R, Saboo B, Misra A. Non-insulin anti-diabetic agents in patients with type 2 diabetes and COVID-19: A critical appraisal of literature. Diabetes Metab Syndr Clin Res Rev. 2021;15(1):159-167. doi: https://doi.org/10.1016/j.dsx.2020.12.026
